PsyBio Therapeutics Corp. (PSYBF)
USD 0.0
(-98.0%)
USD 0.0
(-98.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2022 | 134.63 Thousand USD | 208.24% |
| 2021 | -124.39 Thousand USD | 53.88% |
| 2020 | -269.7 Thousand USD | -66.93% |
| 2019 | -161.56 Thousand USD | 16.53% |
| 2018 | -193.54 Thousand USD | 6.09% |
| 2017 | -206.08 Thousand USD | 18.91% |
| 2016 | -254.15 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q1 | 27.12 Thousand USD | -79.86% |
| 2023 Q2 | 83.76 Thousand USD | 208.84% |
| 2022 Q2 | 149.13 Thousand USD | 11.28% |
| 2022 Q1 | 134.01 Thousand USD | 207.74% |
| 2022 FY | 134.63 Thousand USD | 208.24% |
| 2022 Q3 | -8491.00 USD | -105.69% |
| 2022 Q4 | 134.63 Thousand USD | 1685.67% |
| 2021 Q3 | -506.44 Thousand CAD | -40.93% |
| 2021 FY | -124.39 Thousand USD | 53.88% |
| 2021 Q4 | -124.39 Thousand USD | 75.44% |
| 2021 Q1 | -10.27 Million CAD | -7149.93% |
| 2021 Q2 | -359.36 Thousand CAD | 96.5% |
| 2020 Q2 | -161.56 Thousand USD | -2.65% |
| 2020 Q1 | -157.39 Thousand USD | 0.0% |
| 2020 FY | -269.7 Thousand USD | -66.93% |
| 2020 Q4 | -141.72 Thousand CAD | 0.0% |
| 2019 FY | -161.56 Thousand USD | 16.53% |
| 2018 FY | -193.54 Thousand USD | 6.09% |
| 2017 FY | -206.08 Thousand USD | 18.91% |
| 2016 FY | -254.15 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 10377.786% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 97.616% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 99.685% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 153.938% |
| Rebus Holdings, Inc. | 305 Thousand USD | 55.856% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 102.136% |
| Qrons Inc. | 351.42 Thousand USD | 61.688% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 78.367% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 99.69% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 759.736% |
| Skye Bioscience, Inc. | -5.72 Million USD | 102.353% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 99.146% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 96.73% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 66.495% |
| SQZ Biotechnologies Company | -36.23 Million USD | 100.372% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 93.995% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 85.479% |
| Mesoblast Limited | 55.85 Million USD | 99.759% |
| Marizyme, Inc. | 18.56 Million USD | 99.275% |
| Genus plc | 190.6 Million USD | 99.929% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 93.978% |
| Pharming Group N.V. | 109.8 Million USD | 99.877% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 84.349% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 88.908% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 80.2% |
| ContraFect Corporation | -6.02 Million USD | 102.234% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 88.347% |
| IMV Inc. | 7.67 Million USD | 98.245% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 97.553% |
| MultiCell Technologies, Inc. | 90.04 USD | -149432.43% |
| ONE Bio Corp. | 9.04 Million USD | 98.511% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 118.344% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 98.96% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 90.158% |
| Q BioMed Inc. | 4.06 Million USD | 96.684% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 99.559% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 86.639% |
| Biomind Labs Inc. | 711.4 Thousand USD | 81.074% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 99.778% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 93.266% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 98.949% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 62.57% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 3.694% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -577.702% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 93.886% |
| GB Sciences, Inc. | 1.74 Million USD | 92.295% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 173.258% |
| HST Global, Inc. | 96.79 Thousand USD | -39.1% |
| CSL Limited | 10.52 Billion USD | 99.999% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 34.71% |
| Halberd Corporation | 144.72 Thousand USD | 6.967% |
| Enzolytics Inc. | 981.65 Thousand USD | 86.285% |
| Agentix Corp. | 37.63 Thousand USD | -257.787% |
| Resverlogix Corp. | 6.45 Million USD | 97.913% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 120.003% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.007% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 100.286% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 98.096% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 95.029% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 101.523% |
| AVAX Technologies, Inc. | -5.9 Million USD | 102.281% |
| Zenith Capital Corp. | 10.06 Thousand USD | -1237.828% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.013% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 32.826% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 94.357% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 18.157% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 835.009% |
| Kadimastem Ltd | -253.1 Thousand USD | 153.196% |
| Helix BioMedix, Inc. | -2.57 Million USD | 105.239% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 99.336% |
| BioStem Technologies, Inc. | 4.47 Million USD | 96.989% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 33.1% |
| LadRx Corporation | -2.03 Million USD | 106.611% |
| Cell Source, Inc. | 9.23 Million USD | 98.542% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 78.803% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 78.803% |
| NovAccess Global Inc. | 2.17 Million USD | 93.82% |
| Affymax, Inc. | -5.59 Million USD | 102.406% |
| Itoco Inc. | 228.3 Thousand USD | 41.027% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 0.993% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 97.284% |
| Mobile Lads Corp. | 484.23 Thousand USD | 72.195% |
| CytoDyn Inc. | 20.26 Million USD | 99.336% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 20909.737% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 1552.677% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 98.253% |
| SYBLEU INC | 473.71 Thousand USD | 71.578% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 96.979% |
| International Stem Cell Corporation | 2.59 Million USD | 94.802% |
| Bioxytran, Inc. | 1.89 Million USD | 92.91% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -115.723% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 93.826% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 96.079% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 98.426% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 82.573% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 110.771% |
| Neutra Corp. | 52.18 Thousand USD | -157.993% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 105.409% |
| PureTech Health plc | -167.19 Million USD | 100.081% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 154.975% |
| IXICO plc | -4.44 Million USD | 103.029% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 98.981% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 99.755% |
| CSL Limited | 10.52 Billion USD | 99.999% |
| Cellectis S.A. | -43.81 Million USD | 100.307% |